Keith Ong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Keith Ong has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Gerry Guo
Department of Ophthalmology, Royal North Shore Hospital, St Leonards, New South Wales, Australia
1 shared publication James Smith
Department of Ophthalmology, Royal North Shore Hospital, St Leonards, New South Wales, Australia
1 shared publicationLiane Papantoniou
Department of Ophthalmology, Royal North Shore Hospital, St Leonards, New South Wales, Australia
1 shared publication
Latest Publications
- Open Access
- 17 July 2026
- Published by BMJ in BMJ Case Reports
- Vol. 19 (7) , e271450
Treatment of spontaneous hyphema in Fuch’s heterochromic iridocyclitis with intravitreal anti-VEGF ranibizumab
Fuch’s heterochromic iridocyclitis (FHI) is a unilateral ocular condition characterised by low-grade anterior uveitis. Although the underlying aetiology remains unclear, proposed triggers include infections, autoimmune mechanisms and genetic predisposition. Amsler’s sign is a recognised complication of FHI whereby patients develop spontaneous hyphaema that is often self-limiting. Current management of FHI focuses on managing complications such as raised intraocular pressures (IOPs), secondary glaucoma and formation of cataracts rather than the inflammation itself. In this case report, we present a patient with FHI complicated by spontaneous hyphaema and acute-on-chronic ocular hypertension refractory to medical therapy. Intravitreal anti-vascular endothelial growth factor (anti-VEGF) ranibizumab was used, which achieved rapid resolution of hyphaema with resultant reduction in IOP. Subsequent trabeculectomy was performed for definitive control of persistent chronic ocular hypertension. This case highlights anti-VEGF therapy as a potential adjunctive strategy in selected patients presenting with similar clinical challenges.
- 17 July 2026
- Published by BMJ in BMJ Case Reports
- Vol. 19 (7) , e271450
Open AccessTreatment of spontaneous hyphema in Fuch’s heterochromic iridocyclitis with intravitreal anti-VEGF ranibizumab
Fuch’s heterochromic iridocyclitis (FHI) is a unilateral ocular condition characterised by low-grade anterior uveitis. Although the underlying aetiology remains unclear, proposed triggers include infections, autoimmune mechanisms and genetic predisposition. Amsler’s sign is a recognised complication of FHI whereby patients develop spontaneous hyphaema that is often self-limiting. Current management of FHI focuses on managing complications such as raised intraocular pressures (IOPs), secondary glaucoma and formation of cataracts rather than the inflammation itself. In this case report, we present a patient with FHI complicated by spontaneous hyphaema and acute-on-chronic ocular hypertension refractory to medical therapy. Intravitreal anti-vascular endothelial growth factor (anti-VEGF) ranibizumab was used, which achieved rapid resolution of hyphaema with resultant reduction in IOP. Subsequent trabeculectomy was performed for definitive control of persistent chronic ocular hypertension. This case highlights anti-VEGF therapy as a potential adjunctive strategy in selected patients presenting with similar clinical challenges.